About 40 people gathered at a small church in Cumberland to learn about where their water comes from — and why it’s at risk — ...

Verastem (NASDAQ:VSTM – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both small-cap medical ...

UCLA genetic scientists are reawakening hibernating follicles. A UCLA-discovered molecule, PP405, may finally offer real hope ...

Bayer, Puhe BioPharma ink global license pact to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor: Berlin, Germany Saturday, March 29, 2025, 12:00 Hrs [I ...

Septerna, Inc. ( ($SEPN) ) has released its Q4 earnings. Here is a breakdown of the information Septerna, Inc. presented to its investors.

In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average ...

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A ...

Altasciences, a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership ...

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor ...

While the Inflation Reduction Act’s drug pricing provisions have disrupted seniors’ healthcare, the passage of the EPIC Act ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 80.87%, which has investors questioning if this is right time ...